Cargando…

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

The population pharmacokinetics (PK) of rivaroxaban have been evaluated in several population‐specific models. We developed an integrated population PK model using pooled data from 4,918 patients in 7 clinical trials across all approved indications. Effects of gender, age, and weight on apparent cle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willmann, Stefan, Zhang, Liping, Frede, Matthias, Kubitza, Dagmar, Mueck, Wolfgang, Schmidt, Stephan, Solms, Alexander, Yan, Xiaoyu, Garmann, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980303/ https://www.ncbi.nlm.nih.gov/pubmed/29660785 http://dx.doi.org/10.1002/psp4.12288

Ejemplares similares

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism
por: Reinecke, Isabel, et al.
Publicado: (2020)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism
por: Solms, Alexander, et al.
Publicado: (2020)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects
por: Kubitza, Dagmar, et al.
Publicado: (2014)

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome
por: Zhang, Liping, et al.
Publicado: (2019)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
por: Kubitza, Dagmar, et al.
Publicado: (2018)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
por: Zhang, Liping, et al.
Publicado: (2020)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
por: Liu, Xiao-Qin, et al.
Publicado: (2023)

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study
por: Zhu, Peijuan, et al.
Publicado: (2022)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
por: Burghaus, Rolf, et al.
Publicado: (2011)

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
por: Ruehs, Hauke, et al.
Publicado: (2023)

Population Pharmacokinetic Meta-Analysis to Bridge Ferumoxytol Plasma Pharmacokinetics Across Populations
por: Plock, Nele, et al.
Publicado: (2014)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Ngo, Lien Thi, et al.
Publicado: (2020)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
por: Singkham, Noppaket, et al.
Publicado: (2022)

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
por: Ngo, Lien Thi, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study
por: Kubitza, Dagmar, et al.
Publicado: (2022)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab
por: Morcos, Peter N., et al.
Publicado: (2023)

A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
por: Zhang, Liping, et al.
Publicado: (2017)

Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review
por: Alalawneh, Majdoleen, et al.
Publicado: (2022)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mudu5rkme35mj7bkj86os81igj